These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 22252621)

  • 21. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.
    Lilly MB; Ottmann OG; Shah NP; Larson RA; Reiffers JJ; Ehninger G; Müller MC; Charbonnier A; Bullorsky E; Dombret H; Brigid Bradley-Garelik M; Zhu C; Martinelli G
    Am J Hematol; 2010 Mar; 85(3):164-70. PubMed ID: 20131302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of allogeneic haematopoietic stem cell transplantation in the outcome of Ph+ acute lymphoblastic leukaemia treated with an imatinib-containing regimen.
    Costa LJ
    Br J Haematol; 2009 Sep; 146(5):576-7. PubMed ID: 19555375
    [No Abstract]   [Full Text] [Related]  

  • 23. Prophylactic post-transplant dasatinib administration in a pediatric patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Watanabe A; Chansu S; Ogawa A; Asami K; Imamura M
    Pediatr Int; 2013 Jun; 55(3):e56-8. PubMed ID: 23782380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prolonged survival with imatinib mesylate combined with chemotherapy and allogeneic stem cell transplantation in de novo Ph+ acute myeloid leukemia.
    Sun J; Wang Z; Luo Y; Tan Y; Allan DS; Huang H
    Acta Haematol; 2012; 127(3):143-8. PubMed ID: 22248505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Allogeneic hematopoietic cell transplantation for adult Philadelphia-positive acute lymphoblastic leukemia in the era of tyrosine kinase inhibitors.
    Abou Mourad YR; Fernandez HF; Kharfan-Dabaja MA
    Biol Blood Marrow Transplant; 2008 Sep; 14(9):949-958. PubMed ID: 18721758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Administration of imatinib in the first 90 days after allogeneic hematopoietic cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Chen H; Liu KY; Xu LP; Liu DH; Chen YH; Shi HX; Han W; Zhan XH; Wang Y; Zhao T; Huang XJ
    Chin Med J (Engl); 2011 Jan; 124(2):246-52. PubMed ID: 21362375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reversible cardiotoxicity with tyrosine kinase inhibitors.
    Francis J; Ahluwalia MS; Wetzler M; Wang E; Paplham P; Smiley S; McCarthy PL; Cohen IL; Spangenthal E; Battiwalla M
    Clin Adv Hematol Oncol; 2010 Feb; 8(2):128-32. PubMed ID: 20386534
    [No Abstract]   [Full Text] [Related]  

  • 28. Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lee S; Kim DW; Cho BS; Yoon JH; Shin SH; Yahng SA; Lee SE; Eom KS; Kim YJ; Chung NG; Kim HJ; Min CK; Lee JW; Min WS; Park CW
    Leukemia; 2012 Nov; 26(11):2367-74. PubMed ID: 22705993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trisomy 8 in Philadelphia chromosome negative cell preceding the evolution of a Philadelphia chromosome positive clone with the same additional change during imatinib treatment: revisiting the role of genetic instability in chronic myeloid leukemia.
    Cannella L; Loglisci G; Nanni M; De Cuia MR; Colafigli G; Salaroli A; Serrao A; Alimena G; Breccia M
    Leuk Lymphoma; 2012 Mar; 53(3):497-8. PubMed ID: 21854086
    [No Abstract]   [Full Text] [Related]  

  • 30. Efficacy of hematopoietic stem cell transplantation and prophylactic triple intrathecal therapy in a child with multiple CNS relapse of acute lymphoblastic leukemia.
    Tavil B; Ayçicek A; Azik F; Tunc B; Del Castello BE; Uçkan D
    Clin Transplant; 2013; 27(4):E346-7. PubMed ID: 23781848
    [No Abstract]   [Full Text] [Related]  

  • 31. Overview of second-generation tyrosine kinase inhibitors for patients with imatinib-resistant chronic myelogenous leukemia.
    Ault P
    Clin J Oncol Nurs; 2007 Feb; 11(1):125-9. PubMed ID: 17441403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion.
    Lengline E; Beldjord K; Dombret H; Soulier J; Boissel N; Clappier E
    Haematologica; 2013 Nov; 98(11):e146-8. PubMed ID: 24186319
    [No Abstract]   [Full Text] [Related]  

  • 33. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
    Weisser M; Tischer J; Schnittger S; Schoch C; Ledderose G; Kolb HJ
    Haematologica; 2006 May; 91(5):663-6. PubMed ID: 16627251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dasatinib after allogeneic stem cell transplantation in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.
    de Castro CG; Gregianin LJ; Meneses CF; Brunetto AL
    Pediatr Blood Cancer; 2009 Dec; 53(6):1161. PubMed ID: 19621456
    [No Abstract]   [Full Text] [Related]  

  • 35. In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia.
    Glover JM; Loriaux M; Tyner JW; Druker BJ; Chang BH
    Pediatr Blood Cancer; 2012 Sep; 59(3):576-9. PubMed ID: 22038978
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ph+ ALL: imatinib grows older with patients.
    Bassan R
    Blood; 2014 Feb; 123(6):801-3. PubMed ID: 24505064
    [No Abstract]   [Full Text] [Related]  

  • 37. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid.
    Takayama N; Sato N; O'Brien SG; Ikeda Y; Okamoto S
    Br J Haematol; 2002 Oct; 119(1):106-8. PubMed ID: 12358909
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Second-generation tyrosine kinase inhibitors can induce complete molecular response in Ph-positive acute lymphoblastic leukemia after allogeneic stem cell transplant.
    Fava C; Rege-Cambrin G; Busca A; Gottardi E; Daraio F; Saglio G
    Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S272-5. PubMed ID: 24290212
    [No Abstract]   [Full Text] [Related]  

  • 39. Untreated essential thrombocythemia evolving to biphenotypic leukemia, Philadelphia chromosome positive with monosomy 7: response to imatinib and reduced-intensity allogeneic stem cell transplant.
    Martin SE; DellaValla J
    Leukemia; 2005 Jun; 19(6):1095-6. PubMed ID: 15789065
    [No Abstract]   [Full Text] [Related]  

  • 40. Imatinib for relapsed BCR/ABL positive leukemias.
    Ottmann OG; Wassmann B; Hoelzer D
    Ann Hematol; 2002; 81 Suppl 2():S36-7. PubMed ID: 12611069
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.